FORT LEE, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today announced the European Medicines Agency (EMA) granted Orphan...
After a meeting with the FDA last week, Elevar Therapeutics and Jiangsu Hengrui Pharma are preparing to refile their PD-1 combination potentially as early as October, Elevar’s CEO Saeho Chong, Ph.D., said.
FDA confirmed resubmission can occur without delayFDA confirmed additional GMP and/or BIMO inspections may occur after resubmissionElevar plans to resubmit as soon as possible FORT LEE, N.J., July ...
Phase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival compared with sorafenib as a first-line treatment for uHCCFinal analysis...
FDA rejects Elevar, Hengrui`s PD-1 combo
A post hoc analysis found the efficacy of camrelizumab plus rivoceranib was superior to sorafenib regardless of baseline liver function as measured by both albumin-bilirubin grade and Child-Pugh...
FORT LEE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
PRINCETON, N.J. and FORT LEE, N.J. Oct. 17, 2023 (GLOBE NEWSWIRE) -- Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma), one of China™s largest pharmaceutical companies based on market...
As Elevar Therapeutics and Hengrui Pharmaceuticals await an FDA decision on their combination therapy for newly diagnosed unresectable liver cancer—approved in China back in February—the partners are lining up a new global commercialization pact.
FORT LEE, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...